These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 21949692

  • 1. Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy.
    Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC.
    PLoS One; 2011; 6(9):e24102. PubMed ID: 21949692
    [Abstract] [Full Text] [Related]

  • 2. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak.
    Sun JG, Xiang J, Zeng XL, Li X, Wu P, Fung KP, Liu FY.
    Cancer Lett; 2014 Dec 28; 355(2):253-63. PubMed ID: 25304383
    [Abstract] [Full Text] [Related]

  • 3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S, Dai Y, Harada H, Dent P, Grant S.
    Cancer Res; 2007 Jan 15; 67(2):782-91. PubMed ID: 17234790
    [Abstract] [Full Text] [Related]

  • 4. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
    Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K, Harada M.
    Oncotarget; 2014 Nov 30; 5(22):11399-412. PubMed ID: 25333266
    [Abstract] [Full Text] [Related]

  • 5. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y, Harashima N, Tajima Y, Harada M.
    Oncotarget; 2015 Dec 08; 6(39):41902-15. PubMed ID: 26506422
    [Abstract] [Full Text] [Related]

  • 6. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S.
    Haematologica; 2015 Dec 08; 100(12):1553-63. PubMed ID: 26452980
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells.
    Tsao T, Shi Y, Kornblau S, Lu H, Konoplev S, Antony A, Ruvolo V, Qiu YH, Zhang N, Coombes KR, Andreeff M, Kojima K, Konopleva M.
    Ann Hematol; 2012 Dec 08; 91(12):1861-70. PubMed ID: 22893484
    [Abstract] [Full Text] [Related]

  • 9. Bcl-2 modulation to activate apoptosis in prostate cancer.
    Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E.
    Mol Cancer Res; 2009 Sep 08; 7(9):1487-96. PubMed ID: 19737977
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M, Ruvolo PP.
    Blood; 2015 Jul 16; 126(3):363-72. PubMed ID: 26045609
    [Abstract] [Full Text] [Related]

  • 11. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
    Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, Hu YZ, Lin NM, He QJ, Yang B.
    Mol Cancer Ther; 2011 Jul 16; 10(7):1264-75. PubMed ID: 21566062
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A.
    Clin Cancer Res; 2007 Dec 01; 13(23):7191-8. PubMed ID: 18056200
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
    Clerc P, Carey GB, Mehrabian Z, Wei M, Hwang H, Girnun GD, Chen H, Martin SS, Polster BM.
    PLoS One; 2012 Dec 01; 7(8):e42487. PubMed ID: 22880001
    [Abstract] [Full Text] [Related]

  • 16. Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.
    Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP.
    Clin Cancer Res; 2011 Nov 15; 17(22):7093-104. PubMed ID: 21933888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K, Huang S, Sinicrope FA.
    Clin Cancer Res; 2008 Dec 15; 14(24):8132-42. PubMed ID: 19088028
    [Abstract] [Full Text] [Related]

  • 19. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.
    Apoptosis; 2013 Apr 15; 18(4):492-508. PubMed ID: 23344663
    [Abstract] [Full Text] [Related]

  • 20. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
    Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, Haffty BG.
    Radiat Res; 2014 Dec 15; 182(6):618-25. PubMed ID: 25409124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.